Steven I. Rosenfeld, MD, FACS, specializes in medical and surgical diseases of the cornea, infectious and inflammatory eye diseases, refractive surgery, and cataract surgery, in private practice with Delray Eye Associates, PA. He is a Fellow of the American College of Surgeons and the American Academy of Ophthalmology, an Associate Examiner for the American Board of Ophthalmology, and a Clinical Professor at the Bascom Palmer Eye Institute, University of Miami School of Medicine.
Dr. Rosenfeld is a Phi Beta Kappa graduate from Johns Hopkins University. He obtained his medical degree at the Yale University School of Medicine, where he was elected into the Alpha Omega Alpha Honor Medical Society. He completed his medical internship at Yale/ New Haven Hospital, his ophthalmology residency at Barnes/ Jewish Hospital at Washington University School of Medicine in St. Louis and continued his extensive training with a Heed Foundation Fellowship in Cornea and External Diseases at the Bascom Palmer Eye Institute in Miami.
Dr. Rosenfeld has authored dozens of textbook chapters and scientific articles on the topics of cataract surgery, PRK and LASIK surgery, corneal transplant surgery, and ocular infections. He has co-authored two recent textbooks — one on Lens and Cataract Surgery and one on Refractive Surgery — under the auspices of the American Academy of Ophthalmology. He is on the editorial review boards of EyeNet magazine and Focal Points Clinical Modules and is a reviewer for Ophthalmology and the American Journal of Ophthalmology. Dr. Rosenfeld has been honored with numerous awards from the American Academy of Ophthalmology, including the Achievement Award, Senior Achievement Award, Secretariat for Education Award, and Lifelong Education for the Ophthalmologist Award.
He is a member of the Board of Directors for the Ophthalmic Mutual Insurance Company, the Scientific Advisory Board of NovaBay Pharmaceuticals, the Chair of Ophthalmology for the EHR company Modernizing Medicine, and an Executive Advisor and Consultant to Blue Sea Capital, a private equity company.